<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606593</url>
  </required_header>
  <id_info>
    <org_study_id>AC-057A201</org_study_id>
    <nct_id>NCT00606593</nct_id>
  </id_info>
  <brief_title>Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia</brief_title>
  <official_title>Multicenter, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Dose-finding Study to Evaluate the Efficacy and Safety of Oral Administration of ACT-078573 in Elderly Subjects With Chronic Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midnight Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Midnight Pharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and
      tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with
      primary insomnia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Wake Time After Sleep Onset (WASO)</measure>
    <time_frame>2 treatment nights</time_frame>
    <description>WASO was the time in minutes scored as wake between the onset of persistent sleep and lights on, where the onset of persistent sleep was the beginning of the first continuous 20 epochs (10 min) scored as non-wake.
Mean values were calculated based on 2 treatment PSG nights. PSG nights identified as non-evaluable due to protocol violation were excluded. If a mean value could not be calculated because the value for 1 PSG night was missing or non-evaluable, the valid value for the other PSG night was used. If during a double-blind treatment period a valid PSG was performed but the WASO was missing (e.g., persistent sleep did not occur), the missing value was substituted with the highest value recorded for the subject during the study (single-blind period included).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Total Sleep Time (TST)</measure>
    <time_frame>2 treatment nights</time_frame>
    <description>TST was the amount of actual sleep time measured in minutes scored as non-wake (i.e., sleep stage 1, 2, slow-wave sleep, or rapid eye movement (sleep)).
Mean values were calculated based on 2 treatment PSG nights. PSG nights identified as non-evaluable by protocol violation were excluded. If a mean value could not be calculated because the value for 1 PSG night was missing or non-evaluable, the valid value for the other PSG night was used. If during a double-blind treatment period a valid PSG was performed but the TST was missing (e.g., the subject did not sleep or persistent sleep did not occur), the missing value was substituted with the worst value recorded for the subject during the study (single-blind period included).</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Chronic Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>ABECD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCADE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDBEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DECAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EADBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCEBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEBDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BACED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBDAE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 oral capsules at 25 and 100 mg and matching placebo</intervention_name>
    <description>5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>ABECD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 and matching placebo</intervention_name>
    <description>ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>BCADE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 and matching placebo</intervention_name>
    <description>ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>CDBEA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 and matching placebo</intervention_name>
    <description>ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>DECAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 and matching placebo</intervention_name>
    <description>ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>EADBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 and matching placebo</intervention_name>
    <description>ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>DCEBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 and matching placebo</intervention_name>
    <description>ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 and matching placebo</intervention_name>
    <description>ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>AEBDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 and matching placebo</intervention_name>
    <description>ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>CBDAE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-078573 and matching placebo</intervention_name>
    <description>ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo</description>
    <arm_group_label>BACED</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elderly subjects (&gt; 64 years) with a diagnosis of primary insomnia.

        Exclusion Criteria:

          -  History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental
             Disorders IV (DSM-IV) axis I disorder other than primary insomnia.

          -  Sleep apnea, or restless legs syndrome.

          -  Daytime napping of more than 1 hour per day.

          -  Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2
             years prior to the screening visit.

          -  Unwillingness to refrain from drugs, over-the-counter or herbal medication having an
             effect on sleep or behavior.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James K. Walsh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sleep Medicine and Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Arkansas Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Sleep Medicine Services, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Sleep Medicine Services, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAB Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OmniTrials</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group &amp; Sleep-Wake Disorders Center of South Florida</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurotrials Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Center of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neurophysiology Services, P.C.</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders &amp; Research Center</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Sleep Disorders Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Health Systems</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Sciences Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine Associates P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2008</study_first_posted>
  <results_first_submitted>December 21, 2012</results_first_submitted>
  <results_first_submitted_qc>February 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2013</results_first_posted>
  <disposition_first_submitted>February 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2010</disposition_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>elderly</keyword>
  <keyword>sleeplessness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>242 subjects were screened at 18 centers in the United States and received single-blind placebo treatment. The first subject screening visit was 12 Dec 2007, the first subject was treated on 19 Dec 2007. 112 subjects were randomized, the first assigned double-blind treatment, was on 26 Dec 2007. Last subject, last clinic visit ended on 4 Apr 2008.</recruitment_details>
      <pre_assignment_details>The study consisted of a 2-4-week screening phase on single-blind placebo, a 4-8-week treatment phase, and a 28 day safety follow-up. Subjects were randomized to one of 10 treatment sequences.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence 200/100/P/50/25</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: almorexant (ACT-078573) 200 mg/ACT-078573 100 mg/Placebo/ACT-078573 50 mg/ACT-078573 25mg.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence 100/50/200/25/P</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: ACT-078573 100 mg/ACT-078573 50 mg/ACT-078573 200 mg/ACT-078573 25 mg/placebo.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence 50/25/100/P/200</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: ACT-078573 50 mg/ACT-078573 25 mg/ACT-078573 100 mg/placebo/ACT-078573 200 mg.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence 25/P/50/200/100</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: ACT-078573 25 mg/placebo/ACT-078573 50 mg/ACT-078573 200 mg/ACT-078573 100 mg.</description>
        </group>
        <group group_id="P5">
          <title>Treatment Sequence P/200/25/100/50</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: placebo/ACT-078573 200 mg/ACT-078573 25 mg/ACT-078573 100 mg/ACT-078573 50 mg.</description>
        </group>
        <group group_id="P6">
          <title>Treatment Sequence 25/50/P/100/200</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: ACT-078573 25 mg/ACT-078573 50 mg/placebo/ACT-078573 100 mg/ACT-078573 200 mg.</description>
        </group>
        <group group_id="P7">
          <title>Treatment Sequence P/25/200/50/100</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: placebo/ACT-078573 25 mg/ACT-078573 200 mg/ACT-078573 50 mg/ACT-078573 100 mg.</description>
        </group>
        <group group_id="P8">
          <title>Treatment Sequence 200/P/100/25/50</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: ACT-078573 200 mg/placebo/ACT-078573 100 mg/ACT-078573 25 mg/ACT-078573 50 mg.</description>
        </group>
        <group group_id="P9">
          <title>Treatment Sequence 100/200/50/P/25</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: ACT-078573 100 mg/ACT-078573 200 mg/ACT-078573 50 mg/placebo/ACT-078573 25 mg.</description>
        </group>
        <group group_id="P10">
          <title>Treatment Sequence 50/100/25/200/P</title>
          <description>Study medication was administered in 5 treatment periods, each consisting of 2 consecutive treatment polysomnography (PSG) nights separated by 5-12 days of washout. Treatment consisted of two capsules containing study medication, orally administered on each of the 2 consecutive treatment nights. Treatments were administered in the following sequence: ACT-078573 50 mg/ACT-078573 100 mg/ACT-078573 25 mg/ACT-078573 200 mg/placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11">Randomized participants</participants>
                <participants group_id="P2" count="11">Randomized participants</participants>
                <participants group_id="P3" count="11">Randomized participants</participants>
                <participants group_id="P4" count="11">Randomized participants</participants>
                <participants group_id="P5" count="12">Randomized participants</participants>
                <participants group_id="P6" count="11">Randomized participants</participants>
                <participants group_id="P7" count="11">Randomized participants</participants>
                <participants group_id="P8" count="11">Randomized participants. One participant actually received the treatment sequence 200/P/100/ 50/25</participants>
                <participants group_id="P9" count="12">Randomized participants</participants>
                <participants group_id="P10" count="11">Randomized participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>1st Double-blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2nd Double-blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3rd Double-blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4th Double-blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>5th Double-blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative/Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patient Flow</title>
          <description>The study consisted of a 2-4-week screening phase (including 2 consecutive screening polysomnography (PSG) nights on single blind placebo), a 4- to 8-week treatment phase, and a 28 day safety follow-up. The treatment phase immediately followed randomization and included 5 treatment periods, each consisting of 2 consecutive treatment PSG nights on the assigned study treatment separated by 5 to 12 days of washout. Subjects were randomized to one of 10 treatment sequences.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Wake Time After Sleep Onset (WASO)</title>
        <description>WASO was the time in minutes scored as wake between the onset of persistent sleep and lights on, where the onset of persistent sleep was the beginning of the first continuous 20 epochs (10 min) scored as non-wake.
Mean values were calculated based on 2 treatment PSG nights. PSG nights identified as non-evaluable due to protocol violation were excluded. If a mean value could not be calculated because the value for 1 PSG night was missing or non-evaluable, the valid value for the other PSG night was used. If during a double-blind treatment period a valid PSG was performed but the WASO was missing (e.g., persistent sleep did not occur), the missing value was substituted with the highest value recorded for the subject during the study (single-blind period included).</description>
        <time_frame>2 treatment nights</time_frame>
        <population>Number of evaluable patients for this parameter in the per protocol set. Only subjects with all 5 valid values are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two capsules containing placebo, orally administered on each of 2 consecutive nights</description>
          </group>
          <group group_id="O2">
            <title>ACT-078573 25 mg</title>
            <description>Two capsules containing ACT-078573 25 mg, orally administered on each of 2 consecutive nights</description>
          </group>
          <group group_id="O3">
            <title>ACT-078573 50 mg</title>
            <description>Two capsules containing ACT-078573 50 mg, orally administered on each of 2 consecutive nights</description>
          </group>
          <group group_id="O4">
            <title>ACT-078573 100 mg</title>
            <description>Two capsules containing ACT-078573 100 mg, orally administered on each of 2 consecutive nights</description>
          </group>
          <group group_id="O5">
            <title>ACT-078573 200 mg</title>
            <description>Two capsules containing ACT-078573 200 mg, orally administered on each of 2 consecutive nights</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Wake Time After Sleep Onset (WASO)</title>
          <description>WASO was the time in minutes scored as wake between the onset of persistent sleep and lights on, where the onset of persistent sleep was the beginning of the first continuous 20 epochs (10 min) scored as non-wake.
Mean values were calculated based on 2 treatment PSG nights. PSG nights identified as non-evaluable due to protocol violation were excluded. If a mean value could not be calculated because the value for 1 PSG night was missing or non-evaluable, the valid value for the other PSG night was used. If during a double-blind treatment period a valid PSG was performed but the WASO was missing (e.g., persistent sleep did not occur), the missing value was substituted with the highest value recorded for the subject during the study (single-blind period included).</description>
          <population>Number of evaluable patients for this parameter in the per protocol set. Only subjects with all 5 valid values are included in this analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.1" spread="36.0"/>
                    <measurement group_id="O2" value="98.7" spread="35.5"/>
                    <measurement group_id="O3" value="90.0" spread="35.7"/>
                    <measurement group_id="O4" value="77.7" spread="33.2"/>
                    <measurement group_id="O5" value="62.6" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>Linear model</method>
            <param_type>Least square means treatment effect</param_type>
            <param_value>-10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.0</ci_lower_limit>
            <ci_upper_limit>-3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear model</method>
            <param_type>Least square means treatment effect</param_type>
            <param_value>-19.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.7</ci_lower_limit>
            <ci_upper_limit>-12.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear model</method>
            <param_type>Least square means treatment effect</param_type>
            <param_value>-31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.0</ci_lower_limit>
            <ci_upper_limit>-24.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear model</method>
            <param_type>Least square means treatment effect</param_type>
            <param_value>-46.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.3</ci_lower_limit>
            <ci_upper_limit>-39.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Sleep Time (TST)</title>
        <description>TST was the amount of actual sleep time measured in minutes scored as non-wake (i.e., sleep stage 1, 2, slow-wave sleep, or rapid eye movement (sleep)).
Mean values were calculated based on 2 treatment PSG nights. PSG nights identified as non-evaluable by protocol violation were excluded. If a mean value could not be calculated because the value for 1 PSG night was missing or non-evaluable, the valid value for the other PSG night was used. If during a double-blind treatment period a valid PSG was performed but the TST was missing (e.g., the subject did not sleep or persistent sleep did not occur), the missing value was substituted with the worst value recorded for the subject during the study (single-blind period included).</description>
        <time_frame>2 treatment nights</time_frame>
        <population>Number of evaluable patients for this parameter in the per protocol set. Only subjects with all 5 valid values are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two capsules containing placebo, orally administered on each of 2 consecutive nights</description>
          </group>
          <group group_id="O2">
            <title>ACT-078573 25 mg</title>
            <description>Two capsules containing ACT-078573 25 mg, orally administered on each of 2 consecutive nights</description>
          </group>
          <group group_id="O3">
            <title>ACT-078573 50 mg</title>
            <description>Two capsules containing ACT-078573 50 mg, orally administered on each of 2 consecutive nights</description>
          </group>
          <group group_id="O4">
            <title>ACT-078573 100 mg</title>
            <description>Two capsules containing ACT-078573 100 mg, orally administered on each of 2 consecutive nights</description>
          </group>
          <group group_id="O5">
            <title>ACT-078573 200 mg</title>
            <description>Two capsules containing ACT-078573 200 mg, orally administered on each of 2 consecutive nights</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Sleep Time (TST)</title>
          <description>TST was the amount of actual sleep time measured in minutes scored as non-wake (i.e., sleep stage 1, 2, slow-wave sleep, or rapid eye movement (sleep)).
Mean values were calculated based on 2 treatment PSG nights. PSG nights identified as non-evaluable by protocol violation were excluded. If a mean value could not be calculated because the value for 1 PSG night was missing or non-evaluable, the valid value for the other PSG night was used. If during a double-blind treatment period a valid PSG was performed but the TST was missing (e.g., the subject did not sleep or persistent sleep did not occur), the missing value was substituted with the worst value recorded for the subject during the study (single-blind period included).</description>
          <population>Number of evaluable patients for this parameter in the per protocol set. Only subjects with all 5 valid values are included in this analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.7" spread="43.2"/>
                    <measurement group_id="O2" value="353.8" spread="40.1"/>
                    <measurement group_id="O3" value="360.9" spread="41.7"/>
                    <measurement group_id="O4" value="374.2" spread="39.6"/>
                    <measurement group_id="O5" value="394.7" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear model</method>
            <param_type>Least square means treatment effect</param_type>
            <param_value>14.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.4</ci_lower_limit>
            <ci_upper_limit>21.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear model</method>
            <param_type>Least square means treatment effect</param_type>
            <param_value>21.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.6</ci_lower_limit>
            <ci_upper_limit>28.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear model</method>
            <param_type>Least square means treatment effect</param_type>
            <param_value>34.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.8</ci_lower_limit>
            <ci_upper_limit>41.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear model</method>
            <param_type>Least square means treatment effect</param_type>
            <param_value>55.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.2</ci_lower_limit>
            <ci_upper_limit>62.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events and serious adverse events were collected during each treatment period. Each treatment period included up to 4 days after the last administration of study treatment.</time_frame>
      <desc>Safety population</desc>
      <group_list>
        <group group_id="E1">
          <title>Single-blind Placebo</title>
          <description>Treatment administered during screening period</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Two capsules containing placebo, orally administered on each of 2 consecutive nights</description>
        </group>
        <group group_id="E3">
          <title>ACT-078573 25 mg</title>
          <description>Two capsules containing ACT-078573 25 mg, orally administered on each of 2 consecutive nights</description>
        </group>
        <group group_id="E4">
          <title>ACT-078573 50 mg</title>
          <description>Two capsules containing ACT-078573 50 mg, orally administered on each of 2 consecutive nights</description>
        </group>
        <group group_id="E5">
          <title>ACT-078573 100 mg</title>
          <description>Two capsules containing ACT-078573 100 mg, orally administered on each of 2 consecutive nights</description>
        </group>
        <group group_id="E6">
          <title>ACT-078573 200 mg</title>
          <description>Two capsules containing ACT-078573 200 mg, orally administered on each of 2 consecutive nights</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>EYE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>EYE INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>EYE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>EXOSTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>URETHRAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>RHINITIS SEASONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>PHOTOSENSITIVITY REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pascal Charef/Clinical Trial Leader</name_or_title>
      <organization>Actelion Pharmaceuticals Ltd</organization>
      <phone>+41 61 565 65 65</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

